Skip to main content
NCBI home page
Oncotarget logoLink to Oncotarget
. 2022 Dec 6;13:1305. doi: 10.18632/oncotarget.28316

Addendum: Hyperprogression and impact of tumor growth kinetics after PD1/PDL1 inhibition in head and neck squamous cell carcinoma

Andy Karabajakian 1,✉, Thibaut Garrivier 2, Carole Crozes 3, Nicolas Gadot 4, Jean-Yves Blay 1, Frédéric Bérard 5, Philippe Céruse 6, Philippe Zrounba 7, Pierre Saintigny 4, Charles Mastier 2, Jérôme Fayette 1
PMCID: PMC9725979  PMID: 36473141

This article has an addendum: Patient consent was obtained from the patient. This study was approved by the ethical review board of Centre Léon-Bérard.

Original article: Oncotarget. 2020; 11:1618–1628. 1618-1628. https://doi.org/10.18632/oncotarget.27563

Articles from Oncotarget are provided here courtesy of Impact Journals, LLC

RESOURCES